TY - THES A1 - Schönheit, Jörg T1 - A phagocyte-specific Irf8 gene enhancer establishes early conventional dendritic cell commitment T1 - Ein Phagozyten spezifischer Enhancer des Irf8 Gens steuert die Entwicklung konventioneller dendritischer Zellen N2 - Haematopoietic development is a complex process that is strictly hierarchically organized. Here, the phagocyte lineages are a very heterogeneous cell compartment with specialized functions in innate immunity and induction of adaptive immune responses. Their generation from a common precursor must be tightly controlled. Interference within lineage formation programs for example by mutation or change in expression levels of transcription factors (TF) is causative to leukaemia. However, the molecular mechanisms driving specification into distinct phagocytes remain poorly understood. In the present study I identify the transcription factor Interferon Regulatory Factor 8 (IRF8) as the specification factor of dendritic cell (DC) commitment in early phagocyte precursors. Employing an IRF8 reporter mouse, I showed the distinct Irf8 expression in haematopoietic lineage diversification and isolated a novel bone marrow resident progenitor which selectively differentiates into CD8α+ conventional dendritic cells (cDCs) in vivo. This progenitor strictly depends on Irf8 expression to properly establish its transcriptional DC program while suppressing a lineage-inappropriate neutrophile program. Moreover, I demonstrated that Irf8 expression during this cDC commitment-step depends on a newly discovered myeloid-specific cis-enhancer which is controlled by the haematopoietic transcription factors PU.1 and RUNX1. Interference with their binding leads to abrogation of Irf8 expression, subsequently to disturbed cell fate decisions, demonstrating the importance of these factors for proper phagocyte cell development. Collectively, these data delineate a transcriptional program establishing cDC fate choice with IRF8 in its center. N2 - Die Differenzierung von hämatopoietischen Zellen ist ein komplexer Prozess, der strikt hierarchisch organisiert ist. Dabei stellen die Phagozyten eine sehr heterogene Zellpopulation dar, mit hochspezialisierten Funktionen im angeborenen Immunsystem sowie während der Initialisierung der adaptiven Immunreaktion. Ihre Entwicklung, ausgehend von einer gemeinsamen Vorläuferzelle, unterliegt einer strikten Kontrolle. Die Beeinträchtigung dieser Linienentscheidungsprogramme, z.B. durch Mutationen oder Änderungen der Expressionslevel von Transkriptionsfaktoren kann Leukämie auslösen. Die molekularen Mechanismen, welche die linienspezifische Entwicklung steuern, sind allerdings noch nicht im Detail bekannt. In dieser Arbeit zeige ich den maßgeblichen Einfluss des Transkriptionsfaktors Interferon Regulierender Faktor 8 (IRF8) auf die Entwicklung von dendritischen Zellen (DC) innerhalb der Phagozyten. Mittels einer IRF8-Reporter Maus stellte ich die sehr differenziellen Expressionsmuster von Irf8 in der hämatopoietischen Entwicklung dar. Dabei konnte ich eine neue, im Knochenmark lokalisierte, Vorläuferpopulation isolieren, die in vivo spezifisch Differenzierung in CD8α+ konventionelle dendritische Zellen (cDC) steuert. Dieser Vorläufer ist dabei absolut von der Expression von Irf8 abhängig und etabliert auf transkriptioneller Ebene die dendritische Zellentwicklung, während gleichzeitig die Entwicklung neutrophiler Zellen unterdrückt wird. Darüber hinaus zeigte ich, dass Irf8 Expression während der cDC Entwicklung von einem neu charakterisierten cis-regulatorischen Enhancer abhängt, der spezifisch in myeloiden Zellen agiert. Ich konnte zeigen, dass die hämatopoietischen Transkriptionfaktoren PU.1 und RUNX1 mittels dieses Enhancers die Irf8 Expression steuern. Können diese beiden Faktoren nicht mit dem Enhancer interagieren, führt das zu stark verminderter Irf8 Expression, damit zu Veränderungen in den Differnzierungsprogrammen der Zellen, was die Bedeutung dieses regulatorischen Mechanismus unterstreicht. Zusammengefasst beschreiben diese Daten die Etablierung der frühen cDC Entwicklung, in der IRF8 die zentrale Rolle spielt. KW - Hämatopoiese KW - dendritische Zelle KW - Immunologie KW - Transkiptionsfaktor KW - Genregulation KW - haematopoiesis KW - dendritic cell KW - immunology KW - transcription factor KW - gene regulation Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus-55482 ER - TY - GEN A1 - Lang, Judith A1 - Bohn, Patrick A1 - Bhat, Hilal A1 - Jastrow, Holger A1 - Walkenfort, Bernd A1 - Cansiz, Feyza A1 - Fink, Julian A1 - Bauer, Michael A1 - Schumacher, Fabian A1 - Kleuser, Burkhard A1 - Lang, Karl S. T1 - Acid ceramidase of macrophages traps herpes simplex virus in multivesicular bodies and protects from severe disease T2 - Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe N2 - Macrophages have important protective functions during infection with herpes simplex virus type 1 (HSV-1). However, molecular mechanisms that restrict viral propagation and protect from severe disease are unclear. Here we show that macrophages take up HSV-1 via endocytosis and transport the virions into multivesicular bodies (MVBs). In MVBs, acid ceramidase (aCDase) converts ceramide into sphingosine and increases the formation of sphingosine-rich intraluminal vesicles (ILVs). Once HSV-1 particles reach MVBs, sphingosine-rich ILVs bind to HSV-1 particles, which restricts fusion with the limiting endosomal membrane and prevents cellular infection. Lack of aCDase in macrophage cultures or in Asah1(-/-) mice results in replication of HSV-1 and Asah1(-/-) mice die soon after systemic or intravaginal inoculation. The treatment of macrophages with sphingosine enhancing compounds blocks HSV-1 propagation, suggesting a therapeutic potential of this pathway. In conclusion, aCDase loads ILVs with sphingosine, which prevents HSV-1 capsids from penetrating into the cytosol. T3 - Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe - 1400 KW - immunology KW - infection KW - membrane fusion KW - phagocytosis KW - sphingolipids Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-515661 SN - 1866-8372 IS - 1 ER - TY - JOUR A1 - Lang, Judith A1 - Bohn, Patrick A1 - Bhat, Hilal A1 - Jastrow, Holger A1 - Walkenfort, Bernd A1 - Cansiz, Feyza A1 - Fink, Julian A1 - Bauer, Michael A1 - Schumacher, Fabian A1 - Kleuser, Burkhard A1 - Lang, Karl S. T1 - Acid ceramidase of macrophages traps herpes simplex virus in multivesicular bodies and protects from severe disease JF - Nature Communications N2 - Macrophages have important protective functions during infection with herpes simplex virus type 1 (HSV-1). However, molecular mechanisms that restrict viral propagation and protect from severe disease are unclear. Here we show that macrophages take up HSV-1 via endocytosis and transport the virions into multivesicular bodies (MVBs). In MVBs, acid ceramidase (aCDase) converts ceramide into sphingosine and increases the formation of sphingosine-rich intraluminal vesicles (ILVs). Once HSV-1 particles reach MVBs, sphingosine-rich ILVs bind to HSV-1 particles, which restricts fusion with the limiting endosomal membrane and prevents cellular infection. Lack of aCDase in macrophage cultures or in Asah1(-/-) mice results in replication of HSV-1 and Asah1(-/-) mice die soon after systemic or intravaginal inoculation. The treatment of macrophages with sphingosine enhancing compounds blocks HSV-1 propagation, suggesting a therapeutic potential of this pathway. In conclusion, aCDase loads ILVs with sphingosine, which prevents HSV-1 capsids from penetrating into the cytosol. KW - immunology KW - infection KW - membrane fusion KW - phagocytosis KW - sphingolipids Y1 - 2020 U6 - https://doi.org/10.1038/s41467-020-15072-8 SN - 2041-1723 VL - 11 IS - 1 SP - 1 EP - 15 PB - Nature Publishing Group UK CY - London ER - TY - JOUR A1 - Deutschmann, Claudia A1 - Roggenbuck, Dirk A1 - Schierack, Peter A1 - Rödiger, Stefan T1 - Autoantibody testing by enzyme-linked immunosorbent assay-a case in which the solid phase decides on success and failure JF - Heliyon N2 - Background: The enzyme-linked immunosorbent assay (ELISA) is an indispensable tool for clinical diagnostics to identify or differentiate diseases such as autoimmune illnesses, but also to monitor their progression or control the efficacy of drugs. One use case of ELISA is to differentiate between different states (e.g. healthy vs. diseased). Another goal is to quantitatively assess the biomarker in question, like autoantibodies. Thus, the ELISA technology is used for the discovery and verification of new autoantibodies, too. Of key interest, however, is the development of immunoassays for the sensitive and specific detection of such biomarkers at early disease stages. Therefore, users have to deal with many parameters, such as buffer systems or antigen-autoantibody interactions, to successfully establish an ELISA. Often, fine-tuning like testing of several blocking substances is performed to yield high signal-to-noise ratios.
Methods: We developed an ELISA to detect IgA and IgG autoantibodies against chitinase-3-like protein 1 (CHI3L1), a newly identified autoantigen in inflammatory bowel disease (IBD), in the serum of control and disease groups (n = 23, respectively). Microwell plates with different surface modifications (PolySorp and MaxiSorp coating) were tested to detect reproducibility problems.
Results: We found a significant impact of the surface properties of the microwell plates. IgA antibody reactivity was significantly lower, since it was in the range of background noise, when measured on MaxiSorp coated plates (p < 0.0001). The IgG antibody reactivity did not differ on the diverse plates, but the plate surface had a significant influence on the test result (p = 0.0005).
Conclusion: With this report, we want to draw readers' attention to the properties of solid phases and their effects on the detection of autoantibodies by ELISA. We want to sensitize the reader to the fact that the choice of the wrong plate can lead to a false negative test result, which in turn has serious consequences for the discovery of autoantibodies. KW - biochemistry KW - coatings KW - surface chemistry KW - immunology KW - proteins KW - laboratory medicine KW - clinical research KW - enzyme-linked immunosorbent KW - assay KW - biomarker discovery KW - reproducibility KW - solid-phase KW - autoantibody Y1 - 2020 U6 - https://doi.org/10.1016/j.heliyon.2020.e03270 SN - 2405-8440 VL - 6 IS - 1 PB - Elsevier CY - London [u.a.] ER -